AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
The study utilizes immunoinformatic-based computational methodology to design multi-epitope subunit vaccine by deciphering highly conserved antigenic epitopes across NiV strains by deciphering highly conserved antigenic epitopes across NiV strains.
Dengue virus (DENV) and chikungunya virus (CHIKV) co-infection poses a growing challenge in regions where both arboviruses co-circulate, highlighting the need for integrated vaccine strategies. Here, we designed a multi-epitope subunit vaccine candidate targeting conserved regions of the DENV NS1 protein and the CHIKV...
Rift Valley fever virus (RVFV) is a major zoonotic pathogen causing significant outbreaks in humans and livestock, with no licensed effective vaccines currently available and reverse vaccinology and immunoinformatics approaches were employed to design three multi-epitope mRNA vaccine candidates against RVFV.
An integrated reverse vaccinology strategy is used to identify conserved immunogenic regions from the Envelope protein and NS5 protein, and construct a multi-epitope vaccine for Usutu virus, predicting enhanced humoral and cellular immune-response patterns following repeated antigen administration.
The proposed multi-epitope vaccine shows promising immunological and structural properties, supporting its potential against S. typhimurium, pending experimental validation.
A computationally validated multi-epitope peptide vaccine construct with strong immunogenicity were generated, but validation through the in-vitro and in-vivo study of the developed vaccine is essential to assess its efficacy and immunogenicity profile.
NDVaxWA is a potential vaccine candidate for improved protective efficacy against the currently circulating NDV strains in West Africa and an in silico immune simulation revealed robust humoral and cell mediated responses following vaccination with NDVaxWA.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.